Starling Oncology (STLNW) Other Non Operating Income (2020 - 2026)

Starling Oncology (STLNW) has reported Other Non Operating Income for 7 consecutive years, with -$3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non Operating Income rose 18.66% year-over-year to -$3.2 million; the trailing twelve-month figure through Jun 2026 stood at -$3.2 million (up 56.29% YoY), and the FY2025 full-year result was -$12.2 million, down 552.58% from the prior year.
• Other Non Operating Income fell to -$3.2 million in Q2 2026 per STLNW's latest filing, from $5.0 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $15.5 million in Q3 2022 and bottomed at -$6.0 million in Q3 2025.
• Historically, Other Non Operating Income has averaged $954222.2 across 5 years, with a median of $41500.0 in 2022.
• The sharpest annual moves came in 2022 and 2025: Other Non Operating Income jumped 28622.22% in 2022, then plunged 10767.27% in 2025.
• Over 5 years, Other Non Operating Income stood at $8.7 million in 2022, then tumbled by 113.3% to -$1.2 million in 2023, then jumped by 111.16% to $129000.0 in 2024, then surged by 727.13% to $1.1 million in 2025, then sank by 403.94% to -$3.2 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered -$3.2 million, $5.0 million, and $1.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.